Rare Disease Advancements

🦓 Rare Disease Day is Tomorrow. Over the last year, 8 AI signals have surfaced that hint at how rare disease detection and care are beginning to shift 🔘 A study in npj Digital Medicine showed AI analysing unstructured EHR notes could detect rare diseases like AADC deficiency earlier by spotting subtle symptom patterns across time, potentially shortening diagnostic odysseys 🔘 UCB partnered with Citizen Health to apply AI to opt-in patient communities, using longitudinal real-world data to accelerate research in epilepsy and rare diseases 🔘 AstraZeneca partnered with Pangaea Data to deploy multimodal AI inside EHR systems to surface hidden rare and misdiagnosed patients and connect them to treatments and trials 🔘 Alexion Pharmaceuticals, Inc. also partnered with Pangaea Data to use AI within EHRs to identify undiagnosed hypophosphatasia patients, directly targeting rare-disease diagnostic delays 🔘 Novartis partnered with Atropos Health to use real-world data models to flag potential PNH cases earlier, aiming to reduce years-long diagnostic delays and associated complications 🔘 MENARINI Group teamed up with VisualDx to apply AI-powered image analysis to improve early detection of BPDCN, linking rare cancer identification more directly to targeted therapy 🔘 Novartis and Dawn Health launched Nelia, a digital companion app for rare kidney diseases, extending rare-disease strategy beyond diagnosis into ongoing digital support 🔘 Penn researchers used AI-driven drug repurposing to identify adalimumab as a life-saving treatment for idiopathic multicentric Castleman’s disease, demonstrating AI’s potential in ultra-rare rescue scenarios 💬Diagnosis remains the central challenge in rare disease, and understandably so. But we are now seeing movement beyond detection into digital patient support and AI-informed treatment optimisation. The next phase will likely shift from isolated case-finding tools toward longitudinal, integrated models that support patients across diagnosis, treatment, monitoring, and care navigation #digitalhealth #pharma #ai #raredisease

Honoring Neha's Legacy: How AI, Biotech, and Medical Advancements Offer Hope for Rare Diseases On our daughter's birthday, we remember her courageous 11-year battle with cystic fibrosis (CF) and the indelible impact she had on all of us. When she was diagnosed, CF was considered rare and incurable. We were told that she was just one infection away from losing her fight, and that few companies would invest in a cure for such a small patient population. However, the rapid advancements in AI, machine learning, biotech, medical devices, and groundbreaking therapies in recent years are changing this narrative and giving new hope to patients with rare diseases like CF. One such groundbreaking treatment is Trikafta, developed by Vertex Pharmaceuticals. This transformative medication has been hailed as a game-changer for CF patients, targeting the underlying cause of the disease in up to 90% of patients. While it came too late for Neha, Trikafta has given countless others a chance at a longer, healthier life. Companies like Recursion Pharma are revolutionizing drug discovery by leveraging sophisticated AI algorithms and robotic labs to analyze vast amounts of biological data. Their approach has the potential to slash the time and cost of finding new treatments from years and millions of dollars to mere months and a fraction of the cost. Meanwhile, NVIDIA's CEO, Jensen Huang, is so confident in Recursion's approach that he stated, "If I were to start from nothing, I would do it the way Recursion does it." In the realm of medical devices, companies like Medtronic are developing innovative solutions to improve the lives of patients with rare and chronic conditions. Their recently approved Inceptive device uses advanced neuromodulation to treat chronic pain, adjusting therapy 50 times per second based on the patient's movement and pain levels, avoiding the side effects associated with oral medication. The promise of mRNA technology, as pioneered by companies like Moderna, and gene-editing tools like CRISPR, offer even more hope for tackling rare genetic diseases. These cutting-edge approaches have the potential to correct disease-causing mutations at their source, offering the possibility of one-time, lifelong treatments. These developments fill us with hope that in the near future, rare diseases like CF will no longer be a death sentence, but rather manageable or even curable conditions with targeted, personalized treatments, innovative medical devices, and transformative gene therapies. We can only imagine how different Neha's journey might have been if these technologies had been available to her. In honor of Neha's legacy, we urge you to spread awareness about the transformative potential of AI, biotech, medical devices, and groundbreaking therapies in tackling rare diseases. Together, we can build a world where no family has to endure the heartbreak of losing a loved one to a rare disease. Saritha Prasad Vrittamani

🩸⚡ Johnson & Johnson #Secures FDA #Priority #Review for #IMAAVY® (nipocalimab) — First Potential Approved Therapy for #wAIHA A major breakthrough in rare immunology: Johnson & Johnson receives FDA #Priority #Review for IMAAVY® (nipocalimab-aahu) — positioning it as the first approved treatment for warm autoimmune hemolytic anemia (wAIHA), a life-threatening disease with no approved therapies today. 🗣️ Key leaders • Leonard Dragone, M.D., Ph.D. — Disease Area Leader, Autoantibody & Rheumatology, Johnson & Johnson 1️⃣ 🧬 First-in-class, mechanism-driven approach • Targets FcRn → reduces pathogenic IgG autoantibodies • Addresses root cause of disease, not just symptoms • Preserves essential immune function 👉 Signal: Autoimmune therapy is shifting toward precision immunoselective targeting 2️⃣ 📊 Strong pivotal data (ENERGY trial) • Higher rates of durable hemoglobin response vs placebo • Significant fatigue improvement (key patient outcome) • Phase 2/3 results support clinical relevance 👉 Takeaway: Clinical endpoints are expanding beyond biomarkers → real patient quality-of-life metrics 3️⃣ 🚨 High unmet need in rare disease • No FDA-approved therapies for wAIHA • Current care = off-label steroids + broad immunosuppressants • Serious complications: thrombosis, renal failure, infection 👉 Insight: Rare autoimmune diseases remain high-value innovation opportunities 4️⃣ ⏱️ Accelerated regulatory pathway • Priority Review → ~6-month FDA timeline • First therapy ever granted this designation for wAIHA • Builds on multiple prior FDA designations 👉 Direction: Regulators are prioritizing transformational therapies in underserved diseases 🧩 My takeaway This development reflects a broader shift: ➡️ Immunology is moving from broad suppression → targeted immune modulation ➡️ FcRn inhibition is emerging as a platform across multiple autoantibody diseases ➡️ Rare disease pipelines are becoming core strategic assets for Big Pharma 📌 Bottom line Johnson & Johnson is positioning IMAAVY as a first-in-class, disease-modifying therapy that could redefine the standard of care in wAIHA—and potentially across a broader FcRn-driven immunology portfolio. #Immunology #RareDisease #FDA #Biotech #DrugDevelopment #PrecisionMedicine https://lnkd.in/eQ2-qh-t

FDA’s proposed plausible mechanism pathway is generating a lot of excitement, and just as many questions. I recently spoke with FirstWord Pharma about what this could mean in practice for ultra-rare disease programs, especially in cell and gene therapy. At a high level, the pathway is aimed at highly personalized therapies for diseases with a clear genetic or molecular driver and well-described natural history, where it’s simply not feasible to run large randomized trials. The idea is to anchor approval in a plausible mechanism, strong biology, and carefully characterized patients, potentially with data from very small numbers of patients. In the interview, I focused on three questions I think the field needs answered as we move from concept to implementation: - Statutory fit. Can this pathway operate fully within existing law, using the same standards of adequate and well-controlled evidence that already allow for small, single-arm trials in rare diseases? - Submission expectations. Will sponsors move through the IND framework as usual, with familiar Type B, C, and D interactions, or will there be a distinct submission process for plausible mechanism cases? - CMC requirements. For cell and gene therapies, chemistry, manufacturing, and controls are often the rate-limiting step. It’s important to understand whether CMC expectations will remain the same in this pathway, and at what stage of review they will be evaluated for both clinical testing and marketing applications. From my time at the FDA working on tissue-agnostic approvals, I see clear parallels. The first tissue-agnostic decision for pembrolizumab in MSI-H or mismatch repair deficient solid tumors was a novel way of tying approval to biology and mechanism, rather than a specific organ site, without any change to the underlying statute. I believe plausible mechanism can follow a similar playbook, provided the agency is clear about how it maps to existing accelerated and traditional approval pathways and how post-marketing requirements will be used to confirm long-term benefit. For sponsors, the opportunity is real, but so is the need for precision. The Baby KJ example in the NEJM article has shown us what’s possible for the industry. The next step is translating that narrative into transparent expectations for evidence, CMC, and post-approval data collection that patients, regulators, and developers can trust. Thank you to Virginia Li and the FirstWord Pharma team for the thoughtful discussion. Subscribers can read the full article linked below! #RegulatoryScience #PlausibleMechanismPathway #CMC #CellandGene

🌍 𝗪𝗲𝗲𝗸𝗹𝘆 𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗥𝗼𝘂𝗻𝗱𝘂𝗽 | 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟮𝟬, 𝟮𝟬𝟮𝟱 A dynamic week in rare disease - marked by pivotal readouts, regulatory momentum, and continued investment in next-generation therapies: 💊 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗥𝗲𝗮𝗱𝗼𝘂𝘁𝘀 & 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 Agios Pharmaceuticals’ mitapivat delivered a hemoglobin response in sickle cell disease but missed the mark on reducing pain crises, raising questions about its regulatory path. Scholar Rock outlined plans to bring apitegromab - a muscle-directed therapy for SMA - to market next year. Protara Therapeutics highlighted new paediatric data supporting its cell therapy approach in ultra-rare disease. Early-stage innovation continued with first-patient dosing of Yaqrit’s microbiome therapeutic in PSC/IBD. ⚖️ 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗪𝗶𝗻𝘀 & 𝗗𝗲𝘀𝗶𝗴𝗻𝗮𝘁𝗶𝗼𝗻𝘀 Arrowhead Pharmaceuticals secured its first FDA approval with plozasiran for familial chylomicronemia syndrome - a major milestone for RNAi in metabolic disease. YolTech Therapeutics received FDA IND clearance for a global pivotal trial of its in-vivo gene-editing therapy in PH1. New orphan and regulatory designations spanned cholangiocarcinoma (OBI-902) for OBI Pharma and cutaneous T-cell lymphoma for BioInvent International AB.  Additional approvals included Amgen’s Imdelltra in ES-SCLC and Regeneron EYLEA HD for macular edema. 🔬 𝗣𝗶𝗽𝗲𝗹𝗶𝗻𝗲, 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 & 𝗘𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺 𝗚𝗿𝗼𝘄𝘁𝗵 Thermo Fisher Scientific Fisher launched a Corevitas clinical registry in myasthenia gravis - expanding real-world evidence infrastructure in rare autoimmune disease. Chiesi Group entered an exclusive licensing deal with Aliada (AbbVie) to advance BBB-crossing platforms in lysosomal storage disorders. Avanzanite Bioscience closed a $32M Series A to scale its rare-disease portfolio. Day One Biopharmaceuticals announced plans to acquire Mersana Therapeutics to broaden its mission in paediatric and life-threatening conditions. 👉 The signal is clear: rare disease R&D is accelerating across modalities - from RNAi and gene editing to muscle-directed therapeutics, real-world evidence platforms, and capital formation. 𝘞𝘩𝘪𝘤𝘩 𝘰𝘧 𝘵𝘩𝘦𝘴𝘦 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵𝘴 𝘥𝘰 𝘺𝘰𝘶 𝘵𝘩𝘪𝘯𝘬 𝘸𝘪𝘭𝘭 𝘮𝘰𝘷𝘦 𝘵𝘩𝘦 𝘯𝘦𝘦𝘥𝘭𝘦 𝘮𝘰𝘴𝘵 𝘧𝘰𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘪𝘯 2026 𝘢𝘯𝘥 𝘣𝘦𝘺𝘰𝘯𝘥? ARTO | BioSpace

I watched two companies announce LGMD gene therapy progress this week. One made headlines. The other received less attention. Both deserve recognition. 𝗔𝘁𝗮𝗺𝘆𝗼 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 just dosed their fourth patient with ATA-200. Nine-month data from the first two patients looked "very encouraging." Safety profile held. Muscle biopsies showed early efficacy signals. They're targeting LGMD-R5. A disease so rare that many neurologists may only encounter it once in their career. 𝗕𝗿𝗶𝗱𝗴𝗲𝗕𝗶𝗼 is advancing their LGMD program through the clinic. Different genetic subtype - LGMD-R9. Same heartbreaking progression: children often lose the ability to walk within 10-15 years of symptom onset. Here's what the market access world struggles to discuss openly: These ultra-rare programs face incredibly complex challenges. LGMD-R9 has roughly 5,000 patients across the US and Europe. LGMD-R5 has fewer. Sarepta is already in Phase III for one LGMD subtype. Even if these therapies cure patients, the addressable market might not support the infrastructure to deliver them. 𝗧𝗵𝗲 𝗱𝗶𝗳𝗳𝗶𝗰𝘂𝗹𝘁 𝗿𝗲𝗮𝗹𝗶𝘁𝘆: Manufacturing AAV gene therapy requires significant resources. Building a sales force for 500 US patients presents real sustainability questions. Payer negotiations for populations this small require just as much time and effort as they do for common diseases. So why are companies doing this? Because the science works. Because patient advocacy groups are funding trials when VCs won't. Because researchers like Dr. Barry Byrne believe the platform knowledge gained here scales to bigger markets. And because sometimes you build something that matters more than the ROI model says it should. 𝗪𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝘁𝗲𝗮𝗰𝗵𝗲𝘀 𝗮𝗻𝘆𝗼𝗻𝗲 𝘁𝗿𝘆𝗶𝗻𝗴 𝘁𝗼 𝗯𝗿𝗶𝗻𝗴 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝗺𝗮𝗿𝗸𝗲𝘁: Strategic value isn't always visible in Year 1 revenue forecasts. Atamyo got Fast Track designation. They got Rare Pediatric Disease designation worth a $100M+ priority review voucher. They built manufacturing expertise that transfers to other AAV programs. The real asset isn't the first 500 patients. It's the proof that your platform works. It's the regulatory pathway you carve for future programs. It's the relationships you build with advocacy groups who become champions for your next indication. BridgeBio and Atamyo are committed to a longer timeline than many biotechs can sustain. Not every initiative needs to be profitable in isolation. Some exist to prove capability. Some exist to build infrastructure. Some exist because they're the right thing to do and the financial return follows years later. The question isn't whether LGMD gene therapy will generate blockbuster revenue. The question is what becomes possible once you prove you can cure a disease 5,000 people have? Follow Dr. Suzanne Morgan for breakthroughs in rare disease

300 million people worldwide suffer from rare diseases. 95% have no approved treatment. For decades, this was written off as an unsolvable "market failure." The math was brutal: how do you justify $2.6 billion in development costs for diseases affecting fewer than 200,000 people? But AI is rewriting the economics of impossible. I've been tracking how machine learning is dismantling the barriers that trapped rare disease patients in therapeutic purgatory, and the transformation is staggering: 🎯 Target discovery that took 3-5 years now happens in under 6 months. 🧬 AlphaFold decoded 200 million protein structures—including thousands linked to rare diseases—in 18 months. What structural biologists needed decades to accomplish now takes months. 💰 Drug repurposing is collapsing costs by 95%. 🔍 AI signature matching revealed that edaravone, already approved for stroke, could treat ALS. Cost: $80-$120 million vs $2.6 billion for novel drugs. 👥 Virtual control arms are cutting trial sizes in half. 🤖 Digital twins let us run trials for ultra-rare diseases with 15-20 patients instead of 100+, solving the recruitment crisis that killed 30% of rare disease studies. The data revolution is equally profound. Patient registries, EHRs, wearables, and patient communities like PatientsLikeMe are generating unprecedented insights. We're moving from data scarcity to data abundance—and AI is the translator. But here's what excites me most: this isn't just about faster, cheaper drug development. It's about compressing the "diagnostic odyssey" from 5-7 years to weeks. AI tools like Face2Gene can identify genetic syndromes from facial phenotypes in minutes. The regulatory landscape is adapting too. The FDA are already embracing synthetic control arms, algorithmic endpoints, and in silico trials—recognizing that traditional evidence standards don't work for populations of 1,000 patients. 💵 The economics are becoming viable. 🔄 Precision medicine platforms can be rapidly adapted across diseases, reducing per-condition costs by 60-70%. Outcomes-based pricing ties payments to actual patient results. We're witnessing the transformation of rare diseases from forgotten orphans to innovation powerhouses. The message is clear: no disease should be too rare to treat. The future I see isn't just about curing the uncurable—it's about proving that when technology meets moral imperative, impossible becomes inevitable. #RareDiseases #AIInHealthcare #PrecisionMedicine #DrugDevelopment

Last week ahead of Rare Disease Week, the FDA announced a major shift: approval may no longer require two confirmatory pivotal trials. This is a BIG deal. For 60+ years, drug development has had a structural problem: The patients with the greatest unmet need often receive the least investment. Rare disease is the clearest example. Not because the science isn’t promising. Not because therapies don’t work. Because the economics of regulation made the risk too high. Historically, approval usually meant two large Phase 3 trials. That created a market failure: Biotechs are VC-backed and can’t finance a decade-long regulatory path...and Pharma won’t acquire small-population assets if approval still requires massive capital (despite this being the very basis of precision medicine). So the result : common diseases attracted capital → capital produced approvals → approvals attracted more capital. I call this the medical version of the rich getting richer and the poor getting poorer. Meanwhile, many rare disease therapies with real biological signal stalled after Phase 1 or Phase 2. Allowing a single well-supported pivotal study can materially change this: 1) It fixes the biotech–pharma investment gap Without two massive confirmatory trials: • biotechs can carry programs further • pharma can justify acquiring small-population assets • VCs can fund later stages Therapies that died between Phase 2 and commercialization now have a path forward. I expect more rare-disease portfolios in large pharma and more private investment into gene therapy and precision medicine. 2) It increases the number of Phase 3 trials Reducing burden per program leads to more trials. Previously: one company → one expensive bet Now: one company → multiple programs Capital that funded two trials for one drug can fund multiple diseases. Rare disease hasn’t lacked biology — it has lacked risk tolerance. 3) Real-world data becomes central to approval Real-world evidence is no longer just post-marketing. It becomes foundational: natural history → endpoint selection → patient identification → external control arms → long-term safety follow-up. The new paradigm depends on deep longitudinal patient-level data regulators can trust. What this means: Capital can finally flow toward conditions that historically lacked it. More investment → more trials → more approvals → more treatments. Rare disease should be one of the biggest beneficiaries. At Citizen Health, this is the gap we’ve been working on with patient communities and innovative biotechs — building durable patient relationships and regulatory grade longitudinal datasets usable for trial design, recruitment, and regulatory evidence. This change alone won’t fix the system. But paired with high-quality real-world data and durable patient relationships, it can. And if it works, the biggest winners won’t be companies. It will be families who have waited decades for a therapy to even be attempted.

**Rare Disease Reigns Supreme in CGT** In the US, 85% of eligible, approved CGT products have Orphan Drug Designation. This excludes cord blood products indicated for unrelated donor hematopoietic progenitor cell transplantation procedures (9 products). Of the 26 relevant products approved since 2022, 25 products have Orphan Drug Designation… wow! The pattern is loud and clear… and as I dug into it, I found there are quite a lot of reasons why sponsors have focused on rare disease so far: - Rare diseases are often monogenic with a direct causal driver, making them ideal for gene replacement, gene editing, or engineered cell approaches (also part of the recent ‘Known Mechanism’ concept by FDA for further expediting approvals) - Given the severity of many rare diseases, clinical improvement is often large and clearly measurable with biomarkers, enabling smaller and faster clinical trials.  -  Extreme patient need can drive smaller and fewer clinical trials, sometimes even single-arm studies with natural history comparators, further supported by obtaining RMAT designation to enable use of surrogate endpoints -  Frankly, we still stink at scale-up of most CGT products. Small scale production is our reality, so smaller populations are a better fit to where we are in our CMC journey as an industry - Rare disease treatments command high prices. Payers are willing to pay premium prices for treatments that reduce significant cost from the healthcare system -  Finally, FDA provides meaningful support for rare diseases. Orphan drug designation is designed to support development in small populations via incentives and exclusivity – although I discovered that if a ‘same’ product gets approved and has clinical superiority, it can ‘take over’ exclusivity! (Ouch!) So, it's no surprise that so far, the vast major of the approved CGT products are for rare disease. It’s a wonderful win for those patients who are often overlooked by the biotech industry. Personally, I look forward to the day where CGT products also widely treat diseases with large patient populations… but we have a lot of work ahead of us to get there! #CellTherapy #GeneTherapy #RareDisease #OrphanDrug #RMAT #Biotech #RegulatoryAffairs #AdvancedTherapies

Advancing gene-editing platforms to improve the viability of rare-disease therapeutics: key insights from a 2024 Scientific Exchange hosted by ARM, ISCT, and Daânher Rare-disease therapeutics face viability challenges due to small patient populations and drug-development and regulatory frameworks that were not developed to address rapidly progressive or quickly fatal conditions. Because the majority of rare diseases are genetic in nature, gene-editing modalities offer substantial promise. This Scientific Exchange, co-hosted by the Alliance for Regenerative Medicine, the International Society for Cell and Gene Therapy, and Danaher Corporation in November 2024, set out to address the challenge of realizing the full promise of gene editing for rare-disease therapies by advancing platforms that leverage stable and reusable processes or components to develop multiple therapies. Through multi-stakeholder engagement and discussions of case studies in CRISPR/Cas nuclease, base, and prime editing, 4 key opportunities emerged that deliver value by holding platform elements constant and/or streamlining development steps: (1) consistent delivery vehicle; (2) consistent manufacturing; (3) benefit-risk appropriate quality requirements; and (4) expansive clinical trial designs. Together, these opportunities could yield up to 5-fold efficiency gains and result in substantial value creation for patients, regulators, and developers, potentially decreasing the time required to dose patients with a new gene-editing therapy from years down to 6 months. https://lnkd.in/gVWUPqhW